Charles Sande
Assessing the Impact of SARS-CoV-2 Spike Mutations on Antibody Binding: A Comparative Assessment of the Wuhan and JN.1 Variants' Full-Length Spikes in a Multiplex Luminex Assay.Waweru G, Nyakundi R, Kutima B, Owuor S, Konyino G, Gitonga J, Lugano D, Maina A, Musyoki J, Ochola L, Omondi M, Kariuki CK, Ogongo P, Mwachari C, Shee F, Agoti C, Sande C, Uyoga S, Kagucia E, Agweyu A, Bejon P, Scott JAG, Warimwe GM, Ochola-Oyier LI, Nyagwange J
Viruses, (2025). 17:
Genomic and clinical epidemiology of SARS-CoV-2 in coastal Kenya: insights into variant circulation, reinfection, and multiple lineage importations during a post-pandemic wave.Lambisia AW, Katama EN, Moraa E, Mwita JM, Gallagher K, Mutunga M, Nyale E, Omungala J, Mwanga M, Murunga N, Nyiro J, Nyagwange J, Sande C, Bejon P, Githinji G, Dellicour S, Phan MVT, Cotten M, Ochola-Oyier LI, Holmes EC, Agoti CN
BMC Glob Public Health, (2025). 3:80
Retaining African networks is urgent for global health.Bhiman JN, Serwanga J, Ugwu CA, Vigan-Womas I, Quashie PK, Bhattacharya J, Sande C, Bonomo A, Markey FB, Awandare GA, Garg PK, Kaleebu P, Happi C, Rennergarbe A, Woods C, Kirchner J, Aguilar AO, Makar K, Moore PL
Trends Microbiol, (2025). :
Emergence and transmission dynamics of the FY.4 Omicron variant in Kenya.Musundi S, Mwanga M, Lambisia A, Morobe JM, Murunga N, Moraa E, Ndwiga L, Cheruiyot R, Musyoki J, Mutunga M, Guzman-Rincon LM, Sande C, Mwangangi J, Bejon P, Ochola-Oyier LI, Nokes DJ, Agoti CN, Nyiro J, Githinji G
Virus Evol, (2025). 11:veaf035
Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya.Lugano D, Kutima B, Kimani M, Sigilai A, Gitonga J, Karani A, Akech D, Karia B, Ziraba AK, Maina A, Lambisia A, Omuoyo D, Mugo D, Lucinde R, Owuor S, Konyino G, Newman J, Bailey D, Nduati E, Githinji G, Agoti CN, Bejon P, Scott JAG, Agweyu A, Kagucia W, Warimwe GM, Sande C, Ochola-Oyier LI, Nyagwange J
BMC Infect Dis, (2024). 24:1474
Inno4Vac Workshop Report Part 2: RSV-Controlled Human Infection Model (CHIM) Strain Selection and Immune Assays for RSV CHIM Studies, November 2021, MHRA, UK.Waldock J, Cox RJ, Engelhardt OG, Ascough S, Osterhaus A, Rimmelzwaan GF, Ludlow M, Tregoning JS, McDonald JU, Buchholz UJ, Jeeninga RE, Sande C, Chiu C
Influenza Other Respir Viruses, (2024). 18:e70013
The long-term efficacy of a respiratory syncytial virus vaccine for older adults.Sande CJ
Lancet Infect Dis, (2024). 24:941-942
New SARS-CoV-2 Omicron Variant with Spike Protein Mutation Y451H, Kilifi, Kenya, March-May 2023.Mwanga MJ, Lambisia AW, Morobe JM, Murunga N, Moraa E, Ndwiga L, Cheruiyot R, Musyoki J, Mutunga M, Guzman-Rincon LM, Sande C, Mwangangi J, Bejon P, Ochola-Oyier LI, Nokes DJ, Agoti CN, Nyiro J, Githinji G
Emerg Infect Dis, (2023). 29:
Identifying the research, advocacy, policy and implementation needs for the prevention and management of respiratory syncytial virus lower respiratory tract infection in low- and middle-income countries.Carbonell-Estrany X, Simoes EAF, Bont LJ, Gentile A, Homaira N, Scotta MC, Stein RT, Torres JP, Sheikh J, Broor S, Khuri-Bulos N, Nokes DJ, Munywoki PK, Bassat Q, Sharma AK, Basnet S, Garba M, De Jesus-Cornejo J, Lupisan SP, Nunes MC, Divarathna M, Fullarton JR, Rodgers-Gray BS, Keary I, Renosa MDC, Verwey C, Moore DP, Noordeen F, Kabra S, do Vale MS, Paternina-De La Ossa R, Marino C, Figueras-Aloy J, Krilov L, Berezin E, Zar HJ, Paudel K, Safadi MAP, Dbaibo G, Jroundi I, Jha R, Rafeek RAM, Pinheiro RS, Bracht M, Muthugala R, Lanari M, Martinon-Torres F, Mitchell I, Irimu G, Pandey A, Krishnan A, Mejias A, da Costa MSC, Shrestha S, Pernica JM, de Carvalho FC, Jalango RE, Ibrahim H, Ewa A, Ensinck G, Ulloa-Gutierrez R, Miralha AL, Lucion MF, Hassan MZ, Akhtar Z, Aleem MA, Chowdhury F, Rojo P, Sande C, Musau A, Zaman K, Helena L, Arlant F, Ghimire P, Price A, Subedi KU, Brenes-Chacon H, Goswami DR, Rahman MZ, Hossain ME, Chisti MJ, Vain NE, Lim A, Chiu A, Papenburg J, Juarez MDV, Senaratne T, Arunasalam S, Strand TA, Ayuk A, Ogunrinde O, Tavares LVS, Garba C, Garba BI, Dawa J, Gordon M, Osoro E, Agoti CN, Nyawanda B, Ngama M, Tabu C, Mathew JL, Cornacchia A, Rai GK, Jain A, Giongo MS, Paes BA
Front Pediatr, (2022). 10:1033125
Development of a controlled human infection model to study respiratory syncytial virus infection in older adults.Sande CJ
Lancet Healthy Longev, (2022). 3:e370-e371
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape.Mazur NI, Terstappen J, Baral R, Bardaji A, Beutels P, Buchholz UJ, Cohen C, Crowe JE, Cutland CL, Eckert L, Feikin D, Fitzpatrick T, Fong Y, Graham BS, Heikkinen T, Higgins D, Hirve S, Klugman KP, Kragten-Tabatabaie L, Lemey P, Libster R, Lowensteyn Y, Mejias A, Munoz FM, Munywoki PK, Mwananyanda L, Nair H, Nunes MC, Ramilo O, Richmond P, Ruckwardt TJ, Sande C, Srikantiah P, Thacker N, Waldstein KA, Weinberger D, Wildenbeest J, Wiseman D, Zar HJ, Zambon M, Bont L
Lancet Infect Dis, (2022). 23:e2-e21
Implementation strategies for passive respiratory syncytial virus immunisation.Sande CJ
Lancet Infect Dis, (2021). 21:1200-1201
Respiratory syncytial virus in young children: community cohort study integrating serological surveys, questionnaire and electronic health records, Born in Bradford cohort, England, 2008 to 2013.Zylbersztejn A, Pembrey L, Goldstein H, Berbers G, Schepp R, van der Klis F, Sande C, Mason D, Wright J, Smyth R, Hardelid P
Euro Surveill, (2021). 26:2000023
Vaccination against Respiratory Syncytial Virus.Green CA, Drysdale SB, Pollard AJ, Sande CJ
Interdiscip Top Gerontol Geriatr, (2020). 43:182-192
Priorities for developing respiratory syncytial virus vaccines in different target populations.Drysdale SB, Barr RS, Rollier CS, Green CA, Pollard AJ, Sande CJ
Sci Transl Med, (2020). 12:eaax2466
Author Correction: Airway response to respiratory syncytial virus has incidental antibacterial effects.Sande CJ, Njunge JM, Ngoi JM, Mutunga MN, Chege T, Gicheru ET, Gardiner EM, Gwela A, Green CA, Drysdale SB, Berkley JA, Nokes DJ, Pollard AJ
Nat Commun, (2019). 10:3291
Airway response to respiratory syncytial virus has incidental antibacterial effects.Sande CJ, Njunge JM, Mwongeli Ngoi J, Mutunga MN, Chege T, Gicheru ET, Gardiner EM, Gwela A, Green CA, Drysdale SB, Berkley JA, Nokes DJ, Pollard AJ
Nat Commun, (2019). 10:2218
Agreement between ELISA and plaque reduction neutralisation assay in Detection of respiratory syncytial virus specific antibodies in a birth Cohort from Kilifi, coastal Kenya.Nyiro JU, Kiyuka PK, Mutunga MN, Sande CJ, Munywoki PK, Scott JAG, Nokes DJ
Wellcome Open Res, (2019). 4:33
Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies induced by RSV vaccination and pre-existing antibodies induced by natural infection.Gerretsen HE, Capone S, Vitelli A, Reyes LS, Thompson A, Jones C, Green CA, Pollard AJ, Sande CJ
Vaccine, (2018). 36:6988-6994
Untargeted analysis of the airway proteomes of children with respiratory infections using mass spectrometry based proteomics.Sande CJ, Mutunga M, Muteti J, Berkley JA, Nokes DJ, Njunge J
Sci Rep, (2018). 8:13814
